Advertisement
New Zealand markets closed

  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     

  • NZD/USD

    0.6136
    +0.0015 (+0.24%)
     

  • NZD/EUR

    0.5637
    +0.0008 (+0.15%)
     

  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     

  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     

  • OIL

    80.00
    +0.77 (+0.97%)
     

  • GOLD

    2,419.80
    +34.30 (+1.44%)
     

  • NASDAQ

    18,546.23
    -11.73 (-0.06%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • Dow Jones

    40,003.59
    +134.21 (+0.34%)
     

  • DAX

    18,704.42
    -34.39 (-0.18%)
     

  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • NZD/JPY

    95.4860
    +0.4250 (+0.45%)
     

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

Ventyx Biosciences, Inc.
·1-min read
Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc.

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.

To participate in the conference call, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international) and reference passcode VTYXQ124. A live audio webcast will be available in the Investors section of the Company’s website at www.ventyxbio.com. A recording of the webcast will be available for thirty days following the call.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift inflammation and immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader in the development of oral immunology therapies for peripheral and neuroinflammatory diseases. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com